Aytu BioPharma, Inc.: stock overview

AYTUNASDAQHealthcare · Pharmaceutical Preparations

Price

$1.78

November 13, 2026Market cap $19M

DCF calculator

What Ploutos Investor adds for Aytu BioPharma

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 13 fiscal years, from FY2014
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 20% since Sep 22, 2026, when the 10-K these figures come from was filed ($2.23 then, $1.78 on Nov 13, 2026). The figures date from before that move.10-K
  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

In short

Aytu BioPharma had revenue of $58M in the fiscal year to June 30, 2026 and a net loss of $14M. Revenue fell by 2.6% a year on average over the last 5 years. It pays no dividend.

From its SEC filings (latest fiscal year to June 30, 2026) and the price of November 13, 2026.

Its SEC filings
Market cap
$19M
10.87M shares
P/E
–
Revenue, fiscal year
$58M
-2.6% a year over 5 years
Net margin
-24.8%
FY2025: -20.5%, above 33% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

FY2024–FY2026 fiscal years

-6.0% a year over 2 years

  • FY2026Jun 30, 202610-K
    Revenue$58M
  • FY2025Jun 30, 202510-K
    Revenue$66M
  • FY2024Jun 30, 202410-K
    Revenue$65M

Fiscal years in figures

AYTU's revenue, profit, cash flow and dividend with each year-end price, from FY2014 to FY2023, 10 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $22M
$19M
Enterprise value 
–
P/E 
–
EV / EBIT 
–
EV / Revenue 
–
P/B 3-year median: 0.7
0.6
FCF yield 3-year median: -9.6%
16.8%
Earnings yield 
–

Profitability

Gross margin 
63.9%
Operating margin 
-14.4%
Net margin 3-year median: -24.3%
-24.8%
ROIC 
-17.7%
ROIC, 5-year average 
-41.9%
ROE 
-56.2%

Growth

Revenue, yearly change 
-13.3%
EPS, yearly change 
–
FCF, yearly change 
–
Revenue, average a year 
-2.6%

The yearly change compares FY2026 with FY2025.

Balance sheet

Cash 
$26M
Total debt 
–
Net cash 
–
Net debt / EBITDA 
–
Interest cover 
-4.4x
Current ratio 
–

Balance sheet of June 30, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
–
Total returned 
0.00%
Shares, yearly change 
+9.6%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 28).

Gross margin

69.0%

Above 81% of the 141 companies in its industry, and 86% of all.

Operating margin

-11.8%

Above 39% of the 285 companies in its industry, and 19% of all.

Net margin

-20.5%

Above 33% of the 302 companies in its industry, and 13% of all.

ROE

-95.8%

Above 9% of the 267 companies in its industry, and 4% of all.

ROA

-11.2%

Above 33% of the 313 companies in its industry, and 13% of all.

Revenue growth

1.8%

Above 41% of the 292 companies in its industry, and 34% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
AYTU BIOPHARMA, INC
CIK
1385818
Exchange
NASDAQ
Industry (SIC)
2834 · Pharmaceutical Preparations
Fiscal year ends
June 30
Latest annual report
June 30, 2026
Reporting currency
USD
Shares
10.87M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Aytu BioPharma's filings show?

These are Aytu BioPharma's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about AYTU

Didn't find what you were looking for?

Ask us
What is AYTU's market cap?

Aytu BioPharma, Inc.'s market cap is $19M, at a price of $1.78 on November 13, 2026 and 10.87M shares.

How much revenue does AYTU have?

Aytu BioPharma had revenue of $58M in the fiscal year to June 30, 2026. Over the last 5 years it changed by -2.6% a year on average.

Does AYTU pay a dividend?

No. Aytu BioPharma paid no regular dividend over the last 12 months.

Where do the figures come from?

From Aytu BioPharma, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.